Mechanism of action
Retatrutide (LY3437943) is a triple agonist simultaneously activating GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR) receptors. The GLP-1 component reduces appetite and increases satiety via gastric emptying and the hypothalamus; GIP improves insulin sensitivity and fat distribution; glucagon increases energy expenditure through thermogenesis and promotes lipolysis. This multi-receptor approach is studied for superior synergistic potential versus single or dual agonists.
Research applications
• Energy metabolism and body composition
• GLP-1, GIP and glucagon pathways in weight regulation
• Insulin sensitivity and adipose tissue distribution
• Thermogenesis and lipolysis
Biological properties studied
• Triple GLP-1R, GIPR, GCGR agonism
• Potentially superior metabolic efficacy vs simple/dual agonists
• Modulation of visceral vs subcutaneous fat
• Purity: ≥99% (HPLC)
• Presentation: Lyophilized powder 20 mg
• Storage: 2-8°C
• Recommended diluent: Bacteriostatic water (BA)
Research use only.
